RxDoctor Payments Data

Thomas Hines, MD

Family Medicine · Amarillo, TXNPI 1336141670

Payments from drug & device makers

$2,363in general payments, 2019–2025

Across 46 payments — averaging $51.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$829
  • AstraZeneca$401
  • Pfizer$219
  • Lilly USA, LLC$198
  • Eisai Inc.$140
  • Amgen$125
  • plus $450 from 7 others

What the payments were for

  • Food & beverage$2,355100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,363 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$31,099
Medicare patients
89
Services billed
360

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide35$53,175
TrulicityDulaglutide31$33,659
JardianceEmpagliflozin13$15,494
JanuviaSitagliptin Phosphate14$13,470
PremarinEstrogens, Conjugated23$7,179
Duloxetine Hcl72$3,093
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen118$2,456
Gabapentin78$2,044
SynthroidLevothyroxine Sodium21$1,674
Esomeprazole Magnesium29$1,568
Fentanyl18$1,400
Atorvastatin Calcium146$1,093
Estradiol27$1,064
Albuterol Sulfate HfaAlbuterol Sulfate19$1,007
Omeprazole48$939

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$829$53,17535 claims
Lilly USA, LLCTrulicity$198$33,65931 claims
MerckJanuvia$41$13,47014 claims
PfizerPremarin$219$7,17923 claims
AbbVieSynthroid$125$1,67421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Amarillo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →